南模生物(688265) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥82,932,302.56, representing a decrease of 5.01% compared to the same period last year[4] - Total operating revenue for Q1 2024 was ¥82,932,302.56, a decrease of 5.3% compared to ¥87,304,768.91 in Q1 2023[18] - The net profit attributable to shareholders was -¥12,897,060.70, with a net profit excluding non-recurring items of -¥18,517,804.80[4] - Net loss for Q1 2024 was ¥12,897,060.70, an improvement from a net loss of ¥14,231,619.55 in Q1 2023, indicating a 9.4% reduction in losses[19] - The company's total assets decreased to ¥1,953,324,217.74 in Q1 2024 from ¥1,997,768,441.18 in Q1 2023, a decline of 2.2%[17] - Total liabilities decreased to ¥244,050,810.79 in Q1 2024 from ¥260,985,055.13 in Q1 2023, representing a reduction of 6.5%[17] - The company's total equity attributable to shareholders decreased to ¥1,709,273,406.95 in Q1 2024 from ¥1,736,783,386.05 in Q1 2023, a decline of 1.6%[17] - The basic and diluted earnings per share for Q1 2024 were both -¥0.17, compared to -¥0.18 in Q1 2023, reflecting a slight improvement[19] Cash Flow - The net cash flow from operating activities was -¥28,394,359.82, indicating a significant cash outflow[4] - In Q1 2024, the company's cash inflow from operating activities was CNY 67,757,018.71, compared to CNY 66,448,951.40 in Q1 2023, reflecting a slight increase of 1.96%[22] - The net cash outflow from operating activities improved to CNY -28,394,359.82 in Q1 2024 from CNY -33,872,953.18 in Q1 2023, indicating a reduction in losses by approximately 16.5%[22] - Cash inflow from investment activities totaled CNY 296,496,310.15 in Q1 2024, down from CNY 885,839,718.79 in Q1 2023, representing a decrease of 66.5%[23] - The net cash flow from investment activities was CNY 60,121,373.98 in Q1 2024, compared to CNY 31,629,037.84 in Q1 2023, showing an increase of 90.2%[23] - The company reported a cash outflow from financing activities of CNY 20,983,339.83 in Q1 2024, significantly higher than CNY 6,364,701.52 in Q1 2023, marking an increase of 229.5%[23] - The net increase in cash and cash equivalents for Q1 2024 was CNY 10,740,267.10, contrasting with a decrease of CNY -8,743,172.73 in Q1 2023[23] - The ending balance of cash and cash equivalents rose to CNY 108,343,188.50 in Q1 2024 from CNY 358,699,458.77 in Q1 2023, indicating a decrease of 69.8% year-over-year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,953,324,217.74, down 2.22% from the end of the previous year[5] - The total current assets as of March 31, 2024, amounted to ¥108,343,188.50, an increase from ¥97,602,921.40 as of December 31, 2023, reflecting a growth of approximately 10.8%[15] - The trading financial assets decreased to ¥866,319,453.74 from ¥927,284,641.17, representing a decline of about 6.6%[15] - Accounts receivable increased to ¥128,010,514.23 from ¥108,035,604.85, indicating a rise of approximately 18.5%[15] - Inventory rose to ¥16,853,575.55 compared to ¥15,828,142.53, showing an increase of about 6.4%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,753[9] - The top shareholder, Shanghai Dish Enterprises Management Consulting Co., Ltd., holds 27,771,000 shares, representing 35.62% of total shares[9] - The number of shares held by the top 10 shareholders includes Shanghai Technology Venture Capital Co., Ltd. with 10,576,333 shares, representing 13.57% of total shares[13] - Shanghai Pudong New Emerging Industry Investment Co., Ltd. holds 2,160,000 shares, accounting for 2.77% of total shares[13] - The company has not reported any significant changes in the shareholder structure due to margin trading activities[13] - The total number of shares repurchased by the company as of the report date is 990,229 shares[11] Research and Development - Research and development expenses totaled ¥19,334,427.95, accounting for 23.31% of operating revenue, an increase of 0.63 percentage points year-on-year[5] - Research and development expenses for Q1 2024 were ¥19,334,427.95, slightly down from ¥19,799,024.04 in Q1 2023, showing a decrease of 2.3%[18] - The company has not disclosed any new product developments or technological advancements in this quarter[15] Mergers and Acquisitions - There are no significant mergers or acquisitions reported during this period[15] Audit Information - The company did not conduct an audit for the Q1 financial statements[4] Profitability - The company reported non-recurring gains of ¥5,620,744.10 for the period, primarily from government subsidies and financial asset valuations[6][7] - The company reported a gross profit margin of approximately 43.4% for Q1 2024, compared to 40.0% in Q1 2023, indicating an improvement in profitability[18] - The weighted average return on net assets was -0.75%, an increase of 0.07 percentage points[5]